Loading...
•
Jun 30, 2023
HilleVax Q2 2023 Earnings Report
Reported financial results for the second quarter of 2023 and highlighted recent company progress.
Key Takeaways
HilleVax reported its financial results for the second quarter of 2023. The company had cash, cash equivalents and marketable securities totaling $244.1 million as of June 30, 2023. Net loss for the second quarter 2023 was $27.9 million, compared to $53.9 million for the second quarter 2022.
Completed enrollment of the NEST-IN1 Phase 2b clinical trial with over 3,000 subjects enrolled in six countries.
Appointed Nanette Cocero, Ph.D., MBA, to its Board of Directors.
Topline safety and clinical efficacy data from NEST-IN1 is expected in mid-2024.
Cash, cash equivalents and marketable securities totaled $244.1 million as of June 30, 2023.
Forward Guidance
HilleVax expects topline safety and clinical efficacy data from NEST-IN1 in mid-2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...